Peptides DB
Research-centric peptide and protocol reference hub
Study 30 of 36Abaloparatide (Tymlos) literatureRegenerative therapy · Observational2026

CXCL12-abundant reticular cell lineage is the key source of endosteal osteoblasts and adipocytes in adult bone marrow.

The Cxcl12+ lineage is a key source of endosteal osteoblasts and adipocytes in adult bone marrow, highlighting its potential as a target for age-related bone disease therapies.

Read at Regenerative therapyAdd to compare

Where it sits

this study against the rest of the abaloparatide (tymlos) corpus
9
Preclinical
12
Observational · this one
0
Open-label
3
Randomised
12
Reviews

Summary and findings

This study investigated the contribution of CXCL12-abundant reticular (CAR) cells to osteoblasts and adipocytes in adult bone marrow using a Cxcl12-Cre knock-in mouse model. The findings indicate that the Cxcl12+ lineage accounted for over 60% of endosteal osteoblasts in skeletally mature adult mice. Additionally, this lineage was responsible for the majority of bone marrow adipocytes.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
over 60% of endosteal osteoblasts in skeletally mature adult mice from Cxcl12+ lineage2026

Abstract

The authors’ words, as Regenerative therapy supplied them

Introduction CXCL12-abundant reticular (CAR) cells, characterized by high expression of CXCL12, are perisinusoidal bone marrow stromal cells that establish the hematopoietic stem cell niche. Although CAR cells are postulated to become precursor cells of both osteoblasts and adipocytes, the spatiotemporal dynamics of CAR cells-particularly their contribution to osteoblasts-remain poorly understood. Here, we defined the contribution of the endogenous Cxcl12-expressing (Cxcl12+) lineage to the skeleton from development to adulthood. Methods A novel Cxcl12-Cre knock-in mouse model was generated that allows permanent lineage tracing of CAR cells and their progeny. Results Lineage tracing revealed that the Cxcl12+ lineage arose perinatally and was initially localized around sinusoids in the bone marrow. During aging, these cells expanded and progressively populated non-sinusoidal regions distal to the sinusoids. While the contribution of the lineage to osteogenesis was negligible during postnatal growth, the lineage accounted for over 60% of endosteal osteoblasts in both cortical and trabecular bones in skeletally mature adult mice. Additionally, the lineage gave rise to the majority of bone marrow adipocytes. This lineage did not contribute to periosteal osteoblasts or extra-bone adipocytes. Furthermore, intermittent administration of the anabolic agent parathyroid hormone significantly promoted osteoblast differentiation from this lineage. Single-cell RNA sequencing confirmed the presence of both osteogenic and adipogenic precursors within the traced population. Conclusions The Cxcl12-expression-based lineage tracing approach revealed the CAR cell lineage as the key source of endosteal osteoblasts and adipocytes in adult bone marrow, suggesting their important role in skeletal homeostasis. This lineage may represent a promising therapeutic target for age-related bone diseases.

Elsewhere in the Abaloparatide (Tymlos) corpus

CBone anabolic agents repair alveolar bone damaged by diabetes in mice.International journal of oral science · 2026 · Not reported in abstract.AnimalABeyond antifracture efficacy: Osteoanabolic versus antiresorptive therapy for chronic pain after osteoporotic vertebral fractures. A systematic review and meta-analysis.Bone · 2026 · n=4029 · Not reported in abstract.reviewABone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review.Basic & clinical pharmacology & toxicology · 2023 · n=66 · Not reported in abstract.reviewBReal-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023 · n=102 · Significant increases in lumbar spine BMD at 12 months, P<0.001.HumanDAnti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map.Calcified tissue international · 2026 · Not reported in abstract.reviewDCardiovascular Safety Signals of Osteoporosis Therapies: A FAERS Pharmacovigilance Study.Mediterranean journal of rheumatology · 2026 · Romosozumab demonstrated the highest ROR for MI (2.38) and stroke (3.72).review